BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

954 related articles for article (PubMed ID: 19171173)

  • 21. Vaccination strategy determines the emergence and dominance of CD8+ T-cell epitopes in a FVB/N rat HER-2/neu mouse model of breast cancer.
    Singh R; Paterson Y
    Cancer Res; 2006 Aug; 66(15):7748-57. PubMed ID: 16885378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CpG oligonucleotide as an adjuvant for the treatment of prostate cancer.
    Lubaroff DM; Karan D
    Adv Drug Deliv Rev; 2009 Mar; 61(3):268-74. PubMed ID: 19166887
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Machlenkin A; Paz A; Bar Haim E; Goldberger O; Finkel E; Tirosh B; Volovitz I; Vadai E; Lugassy G; Cytron S; Lemonnier F; Tzehoval E; Eisenbach L
    Cancer Res; 2005 Jul; 65(14):6435-42. PubMed ID: 16024648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
    Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
    Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential CTLs specific for prostate-specific antigen in healthy donors and patients with prostate cancer.
    Elkord E; Williams PE; Kynaston H; Rowbottom AW
    Int Immunol; 2005 Oct; 17(10):1315-25. PubMed ID: 16141246
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modified vaccinia virus Ankara for delivery of human tyrosinase as melanoma-associated antigen: induction of tyrosinase- and melanoma-specific human leukocyte antigen A*0201-restricted cytotoxic T cells in vitro and in vivo.
    Drexler I; Antunes E; Schmitz M; Wölfel T; Huber C; Erfle V; Rieber P; Theobald M; Sutter G
    Cancer Res; 1999 Oct; 59(19):4955-63. PubMed ID: 10519409
    [TBL] [Abstract][Full Text] [Related]  

  • 27. CD8+ T cells against multiple tumor-associated antigens in peripheral blood of midgut carcinoid patients.
    Vikman S; Giandomenico V; Sommaggio R; Oberg K; Essand M; Tötterman TH
    Cancer Immunol Immunother; 2008 Mar; 57(3):399-409. PubMed ID: 17717663
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of a new hTERT-derived HLA-A*0201 restricted, naturally processed CTL epitope.
    Thorn M; Wang M; Kløverpris H; Schmidt EG; Fomsgaard A; Wenandy L; Berntsen A; Brunak S; Buus S; Claesson MH
    Cancer Immunol Immunother; 2007 Nov; 56(11):1755-63. PubMed ID: 17464507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of prostatic acid phosphatase (PAP) specific HLA-DR1-restricted T-cell epitopes.
    Johnson LE; McNeel DG
    Prostate; 2012 May; 72(7):730-40. PubMed ID: 22529020
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in specific immunotherapy for prostate cancer.
    Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M
    Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of T cell epitopes by the use of rapidly generated mRNA fragments.
    Britten CM; Meyer RG; Graf C; Huber C; Wölfel T
    J Immunol Methods; 2005 Apr; 299(1-2):165-75. PubMed ID: 15914199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The presence of prostate-specific antigen-related genes in primates and the expression of recombinant human prostate-specific antigen in a transfected murine cell line.
    Karr JF; Kantor JA; Hand PH; Eggensperger DL; Schlom J
    Cancer Res; 1995 Jun; 55(11):2455-62. PubMed ID: 7538903
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased frequency and responsiveness of PSA-specific T cells after allogeneic hematopoetic stem-cell transplantation.
    Uhlin M; Okas M; Karlsson H; Gertow J; Henningsohn L; Ringdén O; Kärre K; Levitsky V; Mattsson J
    Transplantation; 2009 Feb; 87(4):467-72. PubMed ID: 19307781
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study.
    Hildenbrand B; Sauer B; Kalis O; Stoll C; Freudenberg MA; Niedermann G; Giesler JM; Jüttner E; Peters JH; Häring B; Leo R; Unger C; Azemar M
    Prostate; 2007 Apr; 67(5):500-8. PubMed ID: 17262804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood dendritic cells generated with Flt3 ligand and CD40 ligand prime CD8+ T cells efficiently in cancer patients.
    Davis ID; Chen Q; Morris L; Quirk J; Stanley M; Tavarnesi ML; Parente P; Cavicchiolo T; Hopkins W; Jackson H; Dimopoulos N; Tai TY; MacGregor D; Browning J; Svobodova S; Caron D; Maraskovsky E; Old LJ; Chen W; Cebon J
    J Immunother; 2006; 29(5):499-511. PubMed ID: 16971806
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
    Gulley J; Chen AP; Dahut W; Arlen PM; Bastian A; Steinberg SM; Tsang K; Panicali D; Poole D; Schlom J; Michael Hamilton J
    Prostate; 2002 Oct; 53(2):109-17. PubMed ID: 12242725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Induction of immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen.
    Kim JJ; Yang JS; Nottingham LK; Tang W; Dang K; Manson KH; Wyand MS; Wilson DM; Weiner DB
    Oncogene; 2001 Jul; 20(33):4497-506. PubMed ID: 11494145
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Induction of PSA-specific CTLs and anti-tumor immunity by a genetic prostate cancer vaccine.
    Roos AK; Pavlenko M; Charo J; Egevad L; Pisa P
    Prostate; 2005 Feb; 62(3):217-23. PubMed ID: 15389792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.
    Sinnathamby G; Lauer P; Zerfass J; Hanson B; Karabudak A; Krakover J; Secord AA; Clay TM; Morse MA; Dubensky TW; Brockstedt DG; Philip R; Giedlin M
    J Immunother; 2009 Oct; 32(8):856-69. PubMed ID: 19752748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer.
    Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM
    Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 48.